New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:49 EDTTGT, FB, AAPL, TWTR, BBRY, BAC, ACT, IDCC, BX, AIG, NFLX, QCOM, NVS, GIS, SSNLF, TOn the Fly: Periodicals Wrap
WSJ: AT&T (T) discloses national security requests for thousands of accounts...China acknowledges anti-monopoly probe of Qualcomm (QCOM), InterDigital (IDCC)...Samsung (SSNLF) sees mix of hardware, software for distribution platform...Netflix (NFLX) faces video slowdown as broadband fee issues debated...Actavis (ACT) expected to seek more deals...REUTERS: General Mills (GIS) seeks deals in fast growing emerging markets...AIG (AIG) accused of holding BofA (BAC) $8.5B settlement 'hostage'...Novartis (NVS) Tokyo unit raided by prosecutors...BLOOMBERG: Blackstone (BX) acquires minority stake in Senator Investment Group...BlackBerry (BBRY) CEO blasts T-Mobile for pushing change to iPhones (AAPL)...OTHER NEWS: Banks' cost for Target (TGT) data breach over $200M, AP reports...Twitter (TWTR) could look to follow Facebook (FB) as app distribution platform, Re/code reports.
News For T;QCOM;IDCC;SSNLF;NFLX;ACT;GIS;AIG;BAC;NVS;BX;BBRY;AAPL;TGT;TWTR;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>
January 12, 2015
12:53 EDTAAPLApple falls, levels to watch
Subscribe for More Information
12:45 EDTACTActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
12:10 EDTACTRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
12:04 EDTNVSNovartis sees closing GSK transactions in 1H15
Novartis (NVS) says portfolio transformation is progressing "on track." Sees closing GlaxoSmithKline (GSK) transactions in 1H. In 2015, plans to execute integration of GSK oncology business, execute separation of Vaccines, ensure successful start-up of Consumer Health JV with GSK. Sees NBS to continue to deliver synergies. Comments from slides that are being presented at the JP Morgan Healthcare Conference.
11:48 EDTFBFacebook February volatility elevated at 39
Facebook January call option implied volatility is at 32, January weekly is at 29, February is at 39, March Is at 33; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement.
10:34 EDTGISFood makers slip as Citi highlights headwinds with downgrades in space
Subscribe for More Information
10:24 EDTFBFacebook, Xiaomi held talks over Facebook investment, Reuters says
Subscribe for More Information
10:12 EDTFBFacebook discussed potential investment in Xiaomi, Reuters reports
Subscribe for More Information
09:37 EDTACTSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
09:34 EDTAAPL, TWTRActive equity options trading
Subscribe for More Information
09:04 EDTNFLXAmazon wins first Golden Globe for 'Transparent,' Business Insider reports
Subscribe for More Information
08:37 EDTNVSShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:34 EDTACTActavis expects Q4 non-GAAP EPS to exceed consensus by 10%-15%
Subscribe for More Information
08:21 EDTAAPLApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:18 EDTNFLXNetflix January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
08:09 EDTACTActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTACTActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
06:34 EDTSSNLFSamsung expected to launch two versions of Galaxy S6 phone in March, BI reports
Samsung will launch two versions of its Galaxy S6 phone in March at the Mobile World Congress, Business Insider reports, citing sources. One version will be made with metal, a departure from the plastic casings used in most Galaxy phones, while the other will have a curved screen, the sources say. Reference Link
06:11 EDTSSNLFSamsung, Pattern Energy complete wind energy project in Ontario
Subscribe for More Information
06:06 EDTTSoftcard cuts 60 employees in restructuring, Re/code reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use